Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 3,98€(−98,00%). Der Median liegt bei 3,98€(−98,00%).
Kaufen | 3 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 9 / 15 |
HGI-Strategie | 2 / 18 |
Levermann-Strategie | 3 / 13 |
News
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that leading Medical Centers in the US are approaching the FDA, asking for compassionate use approval to treat patients with pancreatic carcinoma with the company oncological drug Namodenoson.» Mehr auf globenewswire.com
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases (“Can-Fite” or the “Company”), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 of the Company's American Depositary Shares (“ADSs”), at a purchase price of $1.20 per ADS, in a registered direct offering. The offering is expected to close on or about April 15, 2025, subject to satisfaction of customary closing conditions.» Mehr auf globenewswire.com
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Can-Fite's upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 147,18k | - |
Bruttoeinkommen | 147,18k | - |
Nettoeinkommen | −1,84 Mio | - |
EBITDA | −1,91 Mio | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 43,02k€ |
Anzahl Aktien | 43,26k |
52 Wochen-Hoch/Tief | 4,15€ - 0,90€ |
Dividendenrendite | 3,08% |
Dividenden TTM | 6,04€ |
Beta | 0,46 |
KGV (PE Ratio) | −1,15 |
KGWV (PEG Ratio) | −0,04 |
KBV (PB Ratio) | 1,67 |
KUV (PS Ratio) | 24,05 |
Unternehmensprofil
American Tower Corporation, einer der größten globalen REITs, ist ein führender unabhängiger Eigentümer, Betreiber und Entwickler von Mehrmieter-Kommunikationsimmobilien mit einem Portfolio von rund 219.000 Kommunikationsstandorten. Weitere Informationen über American Tower finden Sie in den Abschnitten "Earnings Materials" und "Investor Presentations" auf unserer Investor Relations-Website unter www.americantower.com.
Name | American Tower |
CEO | Motti Farbstein |
Sitz | Petah Tikva, USA |
Website | |
Industrie | Diversifizierte REITs |
Börsengang | |
Mitarbeiter | 5 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | AMT |
Frankfurt | A0T.F |
München | A0T.MU |
Berlin | A0T.BE |
Stuttgart | A0T.SG |
Düsseldorf | A0T.DU |
London | 0HEU.L |
SIX | A0T.SW |
Wien | AMTG.VI |
Milan | 1AMT.MI |
XETRA | A0T.DU |
London Stock Exchange | 0HEU.L |
AMEX | CANF |
Bse | JAIHINDS.BO |
Shz | 300760.SZ |
Assets entdecken
Shareholder von American Tower investieren auch in folgende Assets